TDB Backs Aodh Lifesciences in Breakthrough Pneumonia Drug Development
In line with the Atmanirbhar Bharat vision and India’s goal to lead in affordable healthcare innovation, the Technology Development Board (TDB) under the Department of Science and Technology has partnered with Hyderabad-based Aodh Lifesciences Pvt. Ltd. This support will aid in developing AONEUM-04, a pioneering antibiotic nebulisation suspension designed to treat pneumonia and combat antimicrobial resistance (AMR).
Innovative Treatment Targeting Lung Infections
Unlike traditional oral or injectable antibiotics, AONEUM-04 offers a direct and localised drug delivery method through nebulisation. This allows for a higher concentration of the medicine at the site of infection—deep within the lungs—while significantly reducing side effects linked to systemic circulation.
The formulation boasts several unique features. These include sustained drug release, strong mucoadhesion to lung tissues, and the ability to disrupt biofilms. Together, these characteristics make the treatment more effective and reduce the risk of antibiotic resistance. The innovation is particularly vital for India, where pneumonia remains a leading cause of child deaths and AMR is a growing threat.
Progress Towards Clinical Use and Market Entry
The drug has passed pre-clinical testing and is now preparing for Phase III clinical trials. Once cleared, it will move toward commercial rollout. The treatment is designed to boost patient adherence and lower healthcare costs, offering benefits not only for India but also for other countries facing similar challenges.
Empowering India’s Healthcare Ecosystem
TDB Secretary Shri Rajesh Kumar Pathak noted the importance of this initiative. He said the project addresses two major health issues—pneumonia and AMR—and highlights India’s ability to develop scalable and affordable healthcare technologies.
Leaders at Aodh Lifesciences also expressed optimism. They credited TDB’s backing as a catalyst for progress and committed to delivering patient-focused, safe, and cost-effective therapies to a wider population.
This partnership marks a critical step in strengthening India’s position in global healthcare innovation and enhancing access to life-saving treatments.
